Clinical trial
ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer
NCT00003892 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00003892 |
|---|---|
| Title | ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer |
| Official title | Phase II Study of CGP 69846A (ISIS 5132) in Recurrent Epithelial Ovarian Cancer |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | ISIS 5132 |
| Enrollment | 22 |
| Start date | Feb 1, 1999 |
| Primary completion | Oct 17, 2000 |
| Completion | Sep 22, 2008 |
| First posted | Aug 5, 2004 |
| Last update posted | Apr 6, 2020 |
| Countries | Canada, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: